# Kazia Therapeutics to Host Virtual Event on December 2, 2026: Advancing a New Frontier in Oncology with a First-in-Class Nuclear PD-L1 Protein Degrader - Link: https://www.thailand-business-news.com/pr-news/kazia-therapeutics-to-host-virtual-event-on-december-2-2026-advancing-a-new-frontier-in-oncology-with-a-first-in-class-nuclear-pd-l1-protein-degrader - Published: 2026-11-12T19:00:00+07:00 - Author: PR Newswire | | SYDNEY, Nov. 12, 2026 /PRNewswire/ — [Kazia Therapeutics Limited](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4820254-1&h=366127252&u=https%3A%2F%2Fwww.kaziatx.com%2F&a=Kazia+Therapeutics+Limited)( NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced that it will host a virtual event on Wednesday, December 2, 2026 at 4:00 PM ET featuring management’s overview of NDL2, the Company’s novel nuclear PD-L1 protein degrader designed to address mechanisms of immunotherapy resistance in advanced solid tumors, with an initial focus on metastatic breast cancer and colorectal cancer. NDL2 represents a potentially first-in-class approach within the emerging field of targeted protein degradation, a therapeutic category with no known nuclear PD-L1 protein degraders currently in clinical development. The event will explore the scientific discovery of NDL2 from initial concept through molecular optimization and pre-IND development, highlighting its potential to advance a differentiated approach to cancer immunotherapy. NDL2 is an optimized bicyclic peptide designed to selectively degrade disease-associated nuclear PD-L1 protein, with the goal of restoring the body’s natural anti-tumor immune response. While PD-L1 plays an important role in regulating the immune system, cancer cells can exploit this pathway to evade immune detection and resist treatment. Through targeted protein degradation (TPD), Kazia is pursuing an approach designed to harness the body’s natural protein degradation machinery to target disease-associated proteins, with the potential to overcome limitations of conventional immunotherapies. A live question and answer session will follow the formal presentation. To register, [click here](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4820254-1&h=895662967&u=https%3A%2F%2Flifescievents.com%2Fevent%2Fkwt10h%2F&a=click+here). A replay of the event will be available on the Company’s website following the event. **About Kazia Therapeutics Limited** Kazia Therapeutics Limited (NASDAQ: KZIA) is an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance. Kazia’s lead asset, paxalisib, is an investigational oral, brain-penetrant dual PI3K/mTOR inhibitor being developed across multiple forms of cancer, including cancers of the central nervous system, advanced breast cancer and colorectal cancer. Paxalisib has received U.S. FDA Fast Track and Orphan Drug designations for glioblastoma, Fast Track designation for PI3K-altered brain metastases with radiation and Rare Pediatric Disease and Orphan Drug designations for select pediatric brain tumors, including diffuse intrinsic pontine glioma and atypical teratoid/rhabdoid tumor. Kazia is also advancing two potentially first-in-class preclinical programs: NDL2, a nuclear PD-L1 protein degrader designed to address mechanisms of immunotherapy resistance and metastatic progression, and MSETC, a SETDB1 inhibitor intended to restore immune signaling in tumors that have become resistant to immunotherapy, including checkpoint inhibitors. Additionally, Kazia’s portfolio includes EVT801, a small molecule VEGFR-3 inhibitor that the Company is exploring for potential partnering opportunities. For more information, visit [www.kaziatx.com](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4820254-1&h=2209667009&u=http%3A%2F%2Fwww.kaziatx.com%2F&a=www.kaziatx.com), as well as follow us on [X](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4820254-1&h=61427897&u=https%3A%2F%2Fx.com%2FKaziaTx&a=X) and [LinkedIn](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4820254-1&h=1118683577&u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fkaziatx%2Fhome%2F&a=LinkedIn). **Forward-Looking Statements** This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are generally identified by words such as "anticipates," "believes," "expects," "intends," "plans," "may,"" will," "could," "should," "estimates," "projects," "potential," "suggests," and similar expressions. These forward-looking statements include, but are not limited to, statements regarding: the potential therapeutic benefits, mechanism of action and differentiation of NDL2 and the Company’s other product candidates; the potential for NDL2 to be first-in-class; the anticipated advancement of NDL2 through IND-enabling studies and into clinical development; and the content of the virtual event. NDL2 is an investigational, preclinical-stage therapeutic candidate and has not been approved for clinical use. These forward-looking statements are based on management’s current expectations and assumptions as of the date of this press release and are subject to significant risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied. Such risks and uncertainties include, but are not limited to: the risk that results of preclinical and translational studies may not be predictive of results in clinical trials in humans; the preliminary nature of early-stage data; risks associated with the research and development of therapeutic programs; the Company’s ability to complete IND-enabling studies and submit an IND for NDL2 on the anticipated timeline or at all; the timing, conduct and enrollment of the Company’s clinical trials, including those for paxalisib; regulatory review and approval processes; the Company’s ability to obtain sufficient funding to advance its programs; reliance on third-party collaborators, contract research organizations and trial sites; the Company’s ability to obtain, maintain and protect its intellectual property; competition; general economic and market conditions; and the Company’s ability to maintain compliance with Nasdaq listing requirements. For a more complete discussion of risks and uncertainties, please refer to the Company’s filings with the SEC, including the "Risk Factors" section of the Company’s most recent Annual Report on Form 20-F. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. All forward-looking statements are qualified in their entirety by this cautionary statement. --- | This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. | --- **Read the original article :** [Kazia Therapeutics to Host Virtual Event on December 2, 2026: Advancing a New Frontier in Oncology with a First-in-Class Nuclear PD-L1 Protein Degrader ](https://en.prnasia.com/story/archive/5095229_AE95229_0?rand=184833)